Trial Profile
A Real-world study to evaluate the association between T cell Inflammation Signature (TIS) and the outcomes of anti-PD-1 (Nivolumab or Pembrolizumab) and/or Ipilimumab in patients with advanced Melanoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jun 2018
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Pharmacodynamics; Therapeutic Use
- 20 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology